Look back at pharma news in the week to February 12, 2021

By Barbara Obstoj-Cardwell. Editor

After various delays, the US Food and Drug Administration finally approved Bristol Myers Squibb’s lisocabtagene maraleucel (liso-cel), now branded Breyanzi, for the treatment of B-cell lymphoma. The FDA also gave the green light to Regeneron Pharmaceutical’s biological cholesterol-lowerer Evkeeza (evinacumab-dgnb). On the research front, shares of KalVista Pharma rocketed more than 140%after it released mid-term data on its hereditary angioedema candidate KVD900. Additionally, Gilead Sciences and Dutch partner Galapagos discontinued the Phase III trial of ziritaxestat, marking another blow to their collaboration.

Some good news for liso-cel at last